Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Aug 31;13(8):2095-2097.
doi: 10.21037/tlcr-24-198. Epub 2024 Aug 5.

Clinical insights: five-year follow-up of KEYNOTE-189 trial outcomes and more

Bobby Se  1 , Athar Eysa  2 , Nagla Karim  3
Affiliations
Editorial

Clinical insights: five-year follow-up of KEYNOTE-189 trial outcomes and more

Bobby Se et al. Transl Lung Cancer Res. .
No abstract available

Keywords: KEYNOTE-189; Non-small cell lung cancer (NSCLC); pembrolizumab.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-198/coif). N.K. participates on an advisory board for Jazz, Merck, Pfizer, Amgen, G1 Therapeutics, Novocure, Immunocore, BMS; and is part of the speakers’ Bureau for Regeneron, Astra Zeneca, Sanofi. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med 2018;378:2078-92. 10.1056/NEJMoa1801005 - DOI - PubMed
    1. Merck Sharp & Dohme LLC. Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/ KEYNOTE-189). ClinicalTrials.gov identifier: NCT02578680. Updated July 20 2023. Accessed June 27 2024. Available online: https://clinicaltrials.gov/study/NCT02578680
    1. Garassino MC, Gadgeel S, Speranza G, et al. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. J Clin Oncol 2023;41:1992-8. 10.1200/JCO.22.01989 - DOI - PMC - PubMed
    1. de Castro G, Jr, Kudaba I, Wu YL, et al. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study. J Clin Oncol 2023;41:1986-91. 10.1200/JCO.21.02885 - DOI - PMC - PubMed
    1. Gadgeel S, Rodríguez-Abreu D, Speranza G, et al. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol 2020;38:1505-17. 10.1200/JCO.19.03136 - DOI - PubMed

LinkOut - more resources